Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

249.29
-10.9400-4.20%
Post-market: 249.290.00000.00%19:59 EDT
Volume:2.37M
Turnover:602.65M
Market Cap:16.18B
PE:17.04
High:259.83
Open:257.40
Low:248.52
Close:260.23
52wk High:266.38
52wk Low:122.50
Shares:64.91M
Float Shares:62.69M
Volume Ratio:3.40
T/O Rate:3.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.37
PE(LYR):-42.68

Loading ...

Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative

Simply Wall St.
·
Aug 21

Jazz Pharmaceuticals Advances Phase 3 Xywav Dosing Study in Sleep Disorders

TIPRANKS
·
Aug 20

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed

Simply Wall St.
·
Aug 13

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 12

Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says

MT Newswires Live
·
Aug 11

Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley

TIPRANKS
·
Aug 11

Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 11

Jazz Pharmaceuticals Buys Actio Biosciences for at Least $820 Million

MT Newswires Live
·
Aug 10

Jazz Bets on Epilepsy Treatment with up to $1.32 Billion Deal for Actio

Reuters
·
Aug 10

Jazz Pharmaceuticals - to Buy Actio Biosciences for $820 Mln Upfront, up to $500 Mln Contingent

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Actio Biosciences to Spin Out New Private Entity; Jazz to Receive Minority Stake

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Deal Expected to Close by Q4 2026, Subject to Conditions

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - to Fund Deal with Cash on Hand and Existing Financing Facilities

THOMSON REUTERS
·
Aug 10

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

UBS Adjusts Jazz Pharmaceuticals Price Target to $315 From $307, Maintains Buy Rating

MT Newswires Live
·
Aug 05

Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord

TIPRANKS
·
Aug 05

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Simply Wall St.
·
Aug 05